Follow
Faron Pharmaceuticals Oy
London AIM (United Kingdom)
Nasdaq First North GM (Finland)
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immu Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is a anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Read more

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
News
14 Oct 2020 - 14:15
30 Sep 2020 - 10:45
24 Sep 2020 - 08:15
24 Sep 2020 - 08:00
24 Sep 2020 - 07:44
24 Sep 2020 - 07:41
1 2 3 4 5
Show

10

Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
FARN
FI4000153309
London AIM
United Kingdom (GB)
Details of share in Faron Pharmaceuticals Oy with ticker FARN
Status
Active
SEDOL
Amount of instruments
Par value
Market cap
Currency
Terms
Type
Price
Pre-money valuation
Time
Files
Listing
260 pence
60.1M GBP
17 Nov 2015
Direct listing of Faron Pharmaceuticals Oy on London AIM
Type
Price
Pre-money valuation
Time
Files
Private placement
3.48 GBP
148.36M GBP
21 Apr - 22 Apr 2020
Share issue in Faron Pharmaceuticals Oy
Type
Ticker
ISIN
Market
SHARE
FARON
FI4000153309
Nasdaq First North GM
Finland (FI)
Details of share in Faron Pharmaceuticals Oy with ticker FARON
Status
Active
Order book id
Amount of instruments
46 814 747
Par value
Market cap
Currency
EUR
Segment
Regular
Terms
Type
Price
Pre-money valuation
Time
Files
Listing
03 Dec 2019
Direct listing of Faron Pharmaceuticals Oy on Nasdaq First North GM
Type
Price
Pre-money valuation
Time
Files
Private placement
4.00 EUR
170.53M EUR
21 Apr - 22 Apr 2020
Share issue in Faron Pharmaceuticals Oy
People
Number of Employees
24 people
Markku Jalkanen
CEO
Frank Armstrong
Chairman of the board
Matti Manner
Board member
Gregory B. Brown
Board member
Markku Jalkanen
Board member
John Poulos
Board member
Leopoldo Zambeletti
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Joukahaisenkatu 6
Zip code
205 20
City/district
Turku
Country
Finland (FI)
Registration number
2068285-4
LEI code
7437009H31TO1DC0EB42
First trade date
03 Dec 2019
Registration date
18 Oct 2006
Short name
Faron

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date